Dr Berger founded Health Intelligence Partners 6 years ago as a healthcare consultancy that blends more than 25 years of both business and clinical experience. Prior to founding Health Intelligence Partners, Dr Berger served as senior vice president and chief clinical officer for CVS Caremark. She presently sits on the boards of Care Core National (committees: finance, compensation, search, mergers & acquisitions, and strategic directions), Meals to Heal, The University of Arizona School of Pharmacy, RxAnte, and Midwest Business Group on Health. Dr Berger is the editor-in-chief of The American Journal of Pharmacy Benefits.
Amy Berman, BS, RN
Senior Program Officer
The John A. Hartford Foundation
Berman is a senior program officer with the John A. Hartford Foundation. She heads the Foundation’s development and dissemination of innovative, costeffective models of care that improve health outcomes for older adults. She works to advance palliative care and to reduce avoidable readmissions. Berman also works on collaborations with federal partners, including the Centers for Medicare & Medicaid Innovation, the Office of the National Coordinator for Health Information Technology, and the Administration for Community Living. She has openly shared her experiences living with stage IV breast cancer, presenting to the Institute on Medicine.
See pages SP69, SP70, SP71, SP75, SP85, SP88
Michael E. Chernew, PhD
The American Journal of Managed Care
Dr Chernew is the Leonard D. Schaeffer Professor of Health Care Policy at Harvard Medical School. His research activities focus on several areas, most notably the causes and consequences of growth in healthcare expenditures, geographic variation in medical spending, and use of Value-Based Insurance Design. Dr Chernew is vice chair of the Medicare Payment Advisory Commission, an independent agency established to advise the US Congress on issues affecting the Medicare program. He is also a member of the Congressional Budget Office’s Panel of Health Advisors. In 2010, Dr Chernew was elected to the Institute of Medicine of the National Academy of Sciences; he served on the Committee on the Determination of Essential Health Benefits.
See pages SP91, SP92
VP of Reimbursement & Payer Strategy
Foundation Medicine, Inc
Conway joined Foundation Medicine Inc in May 2012 with over 22 years of sales and executive management experience in the routine clinical and esoteric laboratory marketplaces. His experience includes payer contracting and reimbursement in a wide range of business environments, including Fortune 500 and start-up companies. He has previously worked for Metamark Genetics Inc, a national provider of cancer prognostic tests and services, as vice president of reimbursement and payer contracting.
See pages SP88, SP90
Jeffrey D. Dunn, PharmD, MBA
Senior Vice President
Dr Dunn is senior vice president at VRx, an integrated pharmacy services management company. VRx incorporates PBM functions, pharmacy & therapeutics (P&T)/formulary management, medication therapy management (MTM)/integrated care management (ICM), and government functions for commercial and Medicare Part D employer groups and health plans. Dr Dunn is a board member at VRx and oversees all clinical responsibilities. He manages the P&T process and formularies for commercial and Medicare Part D, as well as all MTM/ICM activities. He is an active member of the Academy of Managed Care Pharmacy, the American Society of Health-System Pharmacists, and the Utah Pharmaceutical Association. He is a reviewer for the Journal of Managed Care Pharmacy and Managed Care Interface, an editor for the International Scholarly Research Network and Oncology Business News, and sits on the editorial board of The American Journal of Managed Care.
See pages SP91, SP92
Kirby Eng, RPh
Director, Oncology Medical Pharmacy Management
Eng is responsible for the development and implementation of oncology specialty drug management strategies for CVS Caremark health plan and employer clients. He has more than 16 years of broad oncology experience in specialty pharmacy, manufacturing, sales and market strategic planning, group purchasing, oncology drug distribution, and provider network management. Before CVS Caremark, he held positions with CuraScript Specialty Pharmacy, US Oncology, Oncology Therapeutics Network (McKesson Specialty), Sicor (Teva), and Eli Lilly and Co. He has been an active participant on National Comprehensive Cancer Network task forces involving oral chemotherapy, specialty pharmacy, and risk evaluation and mitigation strategies.
See pages SP91, SP92
Bruce A. Feinberg, DO
PDF is available on the last page.